Meet our SPARK Fellows
Introducing Cohort 8
Traci Lyons, PhD
Development of a Novel SEMA7A Targeted Therapy to Treat Cancer
Email Address:TRACI.LYONS@CUANSCHUTZ.EDU
Development of a Novel SEMA7A Targeted Therapy to Treat Cancer
We propose developing a humanized SEMA7A-targeted antibody (SmAbH1) as a novel breast cancer treatment. Our mouse monoclonal antibody has shown promising results, promoting full tumor regression in about 60% of tested animals, especially when the immune system is intact. We have also demonstrated its effectiveness in reducing metastasis in mice. The recombinant version (rSmAbH1) binds more effectively to SEMA7A, and we are ramping up manufacturing for further in vivo studies. In our project, we’ll conduct in vivo proof-of-concept studies, humanize rSmAbH1, and test the humanized antibodies in our models.
Learn more about Dr. LyonsCohort 7
Cohort 6
Traci Lyons, PhD
Development of a Novel SEMA7A Targeted Therapy to Treat Cancer
Email Address:TRACI.LYONS@CUANSCHUTZ.EDU
Development of a Novel SEMA7A Targeted Therapy to Treat Cancer
We propose developing a humanized SEMA7A-targeted antibody (SmAbH1) as a novel breast cancer treatment. Our mouse monoclonal antibody has shown promising results, promoting full tumor regression in about 60% of tested animals, especially when the immune system is intact. We have also demonstrated its effectiveness in reducing metastasis in mice. The recombinant version (rSmAbH1) binds more effectively to SEMA7A, and we are ramping up manufacturing for further in vivo studies. In our project, we’ll conduct in vivo proof-of-concept studies, humanize rSmAbH1, and test the humanized antibodies in our models.
Learn more about Dr. LyonsCohort 5
Traci Lyons, PhD
Development of a Novel SEMA7A Targeted Therapy to Treat Cancer
Email Address:TRACI.LYONS@CUANSCHUTZ.EDU
Development of a Novel SEMA7A Targeted Therapy to Treat Cancer
We propose developing a humanized SEMA7A-targeted antibody (SmAbH1) as a novel breast cancer treatment. Our mouse monoclonal antibody has shown promising results, promoting full tumor regression in about 60% of tested animals, especially when the immune system is intact. We have also demonstrated its effectiveness in reducing metastasis in mice. The recombinant version (rSmAbH1) binds more effectively to SEMA7A, and we are ramping up manufacturing for further in vivo studies. In our project, we’ll conduct in vivo proof-of-concept studies, humanize rSmAbH1, and test the humanized antibodies in our models.
Learn more about Dr. Lyons